X-linked Immunodeficient Mice As a Model for Testing the Protective Efficacy of Monoclonal Antibodies Against Pseudomonas Aeruginosa

Overview

Journal Infect Immun

Publisher American Society for Microbiology

Specialty Allergy & Immunology

Date 1988 May 1

PMID 3128480

Citations 7

Authors

H J Zweerink

M C Gammon

C F Hutchison

J J Jackson

G B Pier

J M Puckett

T J Sewell

N H Sigal

Affiliations

Soon will be listed here.

Abstract

(DBA/N[female] X CBA/2[male])F1 males have been reported to be deficient in producing antibodies against a number of antigens, including carbohydrates (I. Scher, Adv. Immunol. 35:1-71, 1982). We show that F1 male mice, in contrast to females, made less lipopolysaccharide (LPS)-specific antibodies after immunization with heat-inactivated Pseudomonas aeruginosa and had significantly less naturally occurring LPS-specific antibodies. Furthermore, neutropenic males were 50 to 1,000 times more sensitive to challenge with representative isolates belonging to the seven Fisher immunotypes. Administration to neutropenic F1 males of a human monoclonal antibody specific for the O carbohydrates of P. aeruginosa immunotype 2 LPS or administration of serum from rabbits immunized with heat-inactivated P. aeruginosa immunotype 1 raised the level of resistance to bacterial challenge close to that of females. The results show that the X-linked immunodeficient mouse is an excellent model with which to test the protective efficacy of P. aeruginosa-specific monoclonal antibodies.

Citing Articles

Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11.

Horn M, Zuercher A, Imboden M, Rudolf M, Lazar H, Wu H Antimicrob Agents Chemother. 2010; 54(6):2338-44.

PMID: 20308370 PMC: 2876355. DOI: 10.1128/AAC.01142-09.

Specificity and function of murine monoclonal antibodies and immunization-induced human polyclonal antibodies to lipopolysaccharide subtypes of Pseudomonas aeruginosa serogroup 06.

Pier G, Koles N, Meluleni G, Hatano K, Pollack M Infect Immun. 1994; 62(4):1137-43.

PMID: 8132318 PMC: 186240. DOI: 10.1128/iai.62.4.1137-1143.1994.

Serum antibody and ocular responses to murine corneal infection caused by Pseudomonas aeruginosa.

Berk R, Montgomery I, Hazlett L Infect Immun. 1988; 56(12):3076-80.

PMID: 3141279 PMC: 259704. DOI: 10.1128/iai.56.12.3076-3080.1988.

Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa.

Zweerink H, Gammon M, Hutchison C, Jackson J, Lombardo D, Miner K Infect Immun. 1988; 56(8):1873-9.

PMID: 3135264 PMC: 259495. DOI: 10.1128/iai.56.8.1873-1879.1988.

In vitro and in vivo activity of polyclonal and monoclonal human immunoglobulins G, M, and A against Pseudomonas aeruginosa lipopolysaccharide.

Pier G, Thomas D, Small G, Siadak A, Zweerink H Infect Immun. 1989; 57(1):174-9.

PMID: 2491835 PMC: 313063. DOI: 10.1128/iai.57.1.174-179.1989.

References

Sawada S, Kawamura T, Masuho Y, Tomibe K . Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa. J Infect Dis. 1985; 152(5):965-70. DOI: 10.1093/infdis/152.5.965. View

Morrison D, Ryan J . Bacterial endotoxins and host immune responses. Adv Immunol. 1979; 28:293-450. DOI: 10.1016/s0065-2776(08)60802-0. View

Cryz Jr S, Furer E, Germanier R . Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide. Infect Immun. 1984; 43(3):795-9. PMC: 264250. DOI: 10.1128/iai.43.3.795-799.1984. View

Stieritz D, Holder I . Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis. 1975; 131(6):688-91. DOI: 10.1093/infdis/131.6.688. View

Briles D, Forman C, Hudak S, CLAFLIN J . Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med. 1982; 156(4):1177-85. PMC: 2186814. DOI: 10.1084/jem.156.4.1177. View

Yother J, Forman C, Gray B, Briles D . Protection of mice from infection with Streptococcus pneumoniae by anti-phosphocholine antibody. Infect Immun. 1982; 36(1):184-8. PMC: 351201. DOI: 10.1128/iai.36.1.184-188.1982. View

Fisher M, Devlin H, Gnabasik F . New immunotype schema for Pseudomonas aeruginosa based on protective antigens. J Bacteriol. 1969; 98(2):835-6. PMC: 284896. DOI: 10.1128/jb.98.2.835-836.1969. View

Cryz Jr S, Furer E, Germanier R . Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect Immun. 1983; 39(3):1072-9. PMC: 348065. DOI: 10.1128/iai.39.3.1072-1079.1983. View

Young L, Armstrong D . Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972; 126(3):257-76. DOI: 10.1093/infdis/126.3.257. View

10.

Pier G, Sidberry H, Zolyomi S, Sadoff J . Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa. Infect Immun. 1978; 22(3):908-18. PMC: 422243. DOI: 10.1128/iai.22.3.908-918.1978. View

11.

Macintyre S, Lucken R, Owen P . Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV. Infect Immun. 1986; 52(1):76-84. PMC: 262200. DOI: 10.1128/iai.52.1.76-84.1986. View

12.

SCHER I . The CBA/N mouse strain: an experimental model illustrating the influence of the X-chromosome on immunity. Adv Immunol. 1982; 33:1-71. DOI: 10.1016/s0065-2776(08)60834-2. View

13.

OBrien A, SCHER I, Campbell G, Macdermott R, Formal S . Susceptibility of CBA/N mice to infection with Salmonella typhimurium: influence of the X-linked gene controlling B lymphocyte function. J Immunol. 1979; 123(2):720-4. View

14.

Sawada S, Suzuki M, Kawamura T, Fujinaga S, Masuho Y, Tomibe K . Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. J Infect Dis. 1984; 150(4):570-6. DOI: 10.1093/infdis/150.4.570. View

15.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

16.

Howard C, Young P, Lee S, DIXON J, Zuckerman A, McALEER W . Hepatitis B surface antigen polypeptide micelles from antigen expressed in Saccharomyces cerevisiae. J Virol Methods. 1986; 14(1):25-35. DOI: 10.1016/0166-0934(86)90004-2. View

17.

Rosenstreich D, Weinblatt A, OBrien A . Genetic control of resistance to infection in mice. Crit Rev Immunol. 1982; 3(4):263-330. View

18.

OBrien A, SCHER I, Metcalf E . Genetically conferred defect in anti-Salmonella antibody formation renders CBA/N mice innately susceptible to Salmonella typhimurium infection. J Immunol. 1981; 126(4):1368-72. View

19.

Forsberg C, BULLEN J . The effect of passage and iron on the virulence of Pseudomonas aeruginosa. J Clin Pathol. 1972; 25(1):65-8. PMC: 477224. DOI: 10.1136/jcp.25.1.65. View

20.

Buhles Jr W, Shifrine M . Adjuvant protection against bacterial infection in granulocytopenic mice. J Infect Dis. 1977; 136(1):90-5. DOI: 10.1093/infdis/136.1.90. View